Durable Remission Seen in Two CLL Patients After CAR T Cell Therapy

TUESDAY, Feb. 15, 2022 (HealthDay News) -- Long-term chimeric antigen receptor (CAR) T cell signaling and persistence has been demonstrated at more than 10 years after infusion in two chronic lymphocytic leukemia (CLL) patients, according to a study published online Feb. 2 in Nature.
J. Joseph Melenhorst, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues examined the longest persisting CD19-redirected CAR T cells to date in two CLL patients who achieved a complete remission in 2010.
The researchers found that the CAR T cells were detectable up to more than 10 years after infusion; in both patients, remission was sustained. In both patients, a highly activated CD4+ population emerged, which dominated the CAR T cell population at later time points. The clonal make-up of CAR T cells was stable, reflecting this transition, with a few clones dominating the repertoire. Together with ongoing functional activation and proliferation, these long-persisting CD4+ CAR T cells exhibited cytotoxic characteristics.
"This long-term remission is remarkable, and witnessing patients living cancer-free is a testament to the tremendous potency of this 'living drug' that works effectively against cancer cells," Melenhorst said in a statement.
Several study authors hold patents related to CAR T cell manufacturing and biomarker discovery, and two authors are employees of Novartis, which helped fund the study.
Abstract/Full Text (subscription or payment may be required)
Related Posts
¿Tiene ‘fatiga de Zoom’? Descansar de la cámara puede ayudar
JUEVES, 2 de septiembre de 2021 (HealthDay News) -- Si se siente exhausto tras...
All-Inside Meniscal Repair Effective in Long Term
FRIDAY, Aug. 4, 2023 (HealthDay News) -- All-inside meniscal repair is...
Even in His Youth
In 1994, Kurt Cobain took his life at the age of 27. Like Jimi Hendrix, Janis...
CDC Says Universal Masking Can Be Dropped in Some Nursing Homes, Hospitals
MONDAY, Sept. 26, 2022 (HealthDay News) -- The U.S. Centers for Disease Control...